Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, Oliver Movadat,

Slides:

Advertisements

Similar presentations

Advertisements

Prediction and prevention of allergic rhinitis: A birth cohort study of 20 years Linus B. Grabenhenrich, MD, MPH, Thomas Keil, MD, MSc, Andreas Reich,

Volume 11, Pages (September 2016)

Volume 10, Pages (August 2016) A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects Erin M. Scherer,

Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure Philipp Badorrek, MD,

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study Anna.

Volume 11, Pages (September 2016)

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R

Corinne A. Keet, MD, MS, Pamela A

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Statistical Considerations of Food Allergy Prevention Studies

Identification of common allergenic structures in mugwort and ragweed pollen Reinhold Hirschwehr, MDa, Claudia Heppner, MSca, Susanne Spitzauer, MDb,

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine Alina F. Dumitru, MD, Mohamed.

Prediction of IgE-binding epitopes by means of allergen surface comparison and correlation to cross-reactivity Fabio Dall'Antonia, PhD, Anna Gieras,

Frequent occurrence of T cell–mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments Raffaela Campana, PhD, Katharina.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy Margarete Focke-Tejkl, PhD, Milena.

Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy Raphaela.

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32 Verena Niederberger, MD, Angela Neubauer, PhD,

Assessing basophil activation by using flow cytometry and mass cytometry in blood stored 24 hours before analysis Kaori Mukai, PhD, Nicolas Gaudenzio,

Persistence of the IgE repertoire in birch pollen allergy

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

The component-specific to total IgE ratios do not improve peanut and hazelnut allergy diagnoses Linus Grabenhenrich, MD, MPH, Lars Lange, MD, Magdalena.

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study Anna.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.

Mismatch Receptive Fields in Mouse Visual Cortex

Blood DNA methylation biomarkers predict clinical reactivity in food-sensitized infants David Martino, PhD, Thanh Dang, PhD, Alexandra Sexton-Oates, BSc,

In vivo allergenic activity of a hypoallergenic mutant of the major fish allergen Cyp c 1 evaluated by means of skin testing Nikolaos Douladiris, MD,

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults Christian Lupinek, MD,

Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season Alexander Kettner, PhD, Gilles DellaCorte, MD,

Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J

Component-Resolved Diagnosis (CRD) of Type I Allergy with Recombinant Grass and Tree Pollen Allergens by Skin Testing Susanne Heiss, Rudolf Valenta

What Color is it?.

Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5 Margarete Focke-Tejkl, PhD, Raffaela Campana, PhD, Renate.

Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms Raffaela.

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors Donald W. MacGlashan, MD, PhD,

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Journal of Allergy and Clinical Immunology

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Determination of IgE and IgG reactivity to more than 170 allergen molecules in paper- dried blood spots Victoria Garib, MD, PhD, Eva Rigler, MD, PhD,

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Altered metabolic profile in patients with IgE to galactose-alpha-1,3-galactose following in vivo food challenge John W. Steinke, PhD, Shawna L. Pochan,

Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R

Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy Eva Wollmann,

Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy Kuan-Wei Chen, PhD, Petra Zieglmayer,

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children Yvonne Resch, MSc, Sven Michel, MSc, Michael Kabesch, MD,

Skin test evaluation of a novel peptide carrier–based vaccine, BM32, in grass pollen– allergic patients Verena Niederberger, MD, Katharina Marth, MD,

Corinne A. Keet, MD, MS, Pamela A

Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy Véronique Schulten, PhD,

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

CD23 surface density on B cells is associated with IgE levels and determines IgE- facilitated allergen uptake, as well as activation of allergen-specific.

A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS Katarzyna Niespodziana, MSc, Margarete Focke-Tejkl, PhD, Birgit.

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract Anil Nanda, MD, Maeve O'Connor, MD,

Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly Raffaela Campana, PhD, Susanne Vrtala,

Regina Selb, PhD, Julia Eckl-Dorna, MD, PhD, Teresa E

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

The IgE-Reactive Autoantigen Hom s 2 Induces Damage of Respiratory Epithelial Cells and Keratinocytes via Induction of IFN-γ Irene Mittermann, Renate.

Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy Teresa E. Twaroch, MSc, Margit Focke, PhD, Vera Civaj, Milena.

Presentation transcript:

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, Oliver Movadat, Eva Wollmann, Carolin Cornelius, Milena Weber, Renate Fröschl, Regina Selb, Katharina Blatt, Dubravka Smiljkovic, Volker Schoder, René Cervenka, Thomas Plaichner, Gottfried Stegfellner, Hans Huber, Rainer Henning, Justyna Kozik-Jaromin, Thomas Perkmann, Verena Niederberger, Ventzislav Petkov, Peter Valent, Adelheid Gauly, Hans Peter Leinenbach, Ingrid Uhlenbusch-Koerwer, Rudolf Valenta EBioMedicine Volume 17, Pages 119-133 (March 2017) DOI: 10.1016/j.ebiom.2017.02.007 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Enrollment, randomization and study design. (a) After screening (yellow; AV1, CV1 in b), subjects were allocated to the apheresis (blue) or the control group (pink). (b) Treatment-visits (AV2, AV3, etc.) are indicated by blue boxes, corresponding visits of the control group (CV2, CV3, etc.) by pink boxes. Intervals between treatment weeks, including control visits (AV5, CV4, etc.) are shown in white. The study was completed after a follow-up visit in week 16 (orange; AV14 and CV11). Weeks after randomization are shown at the bottom. pt./pts. – patient/s; IC – informed consent; AV – visit apheresis group; CV – visit control group. EBioMedicine 2017 17, 119-133DOI: (10.1016/j.ebiom.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Relative IgE-depletion and absolute IgE-levels. (a) Mean (±SD) depletion rates (y-axes: % IgE-reduction) of total IgE (top chart), IgE to seasonal (center) and perennial allergen sources (bottom) are shown for each treatment visit (x-axes) of the apheresis group. (b) Absolute total IgE-levels (y-axis: U/ml) are shown as box-and-whisker plots for the screening visit, the first (Start) and the last visit (End) of each treatment cycle, for control- and follow-up visits (x-axis). Blue boxes show results for the treatment, red boxes for the control group, outliers are indicated by circles. The dashed line corresponds to median total IgE-levels for both groups at the screening visit. Significant differences between start and end of the respective cycle are indicated (**p≤0.01). EBioMedicine 2017 17, 119-133DOI: (10.1016/j.ebiom.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Isotype specificity of IgEnio. Relative changes (y-axis: % changes to pre-treatment values) in serum IgM (gray), IgG (green), IgA (orange) and albumin (purple) are shown for each treatment cycle (x-axis) for the apheresis group. Error bars represent mean relative changes±standard deviations. Significant differences to changes in serum albumin are indicated (**p≤0.01). EBioMedicine 2017 17, 119-133DOI: (10.1016/j.ebiom.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Fig. 4 Changes in allergen-specific skin- and basophil-reactivity and in sIgE-levels. Relative changes (y-axes: fold changes) of (a) total wheal-areas from skin prick testing (SPT) and (b) of basophil-sensitivity (CD203c BAT – basophil activation test measuring CD203c upregulation; AUC – area under the curve) are shown as scatter plots for control and follow-up visits (x-axes) for birch (left) and grass pollen allergens (right). Results from individual subjects are colour-coded and displayed for the apheresis (filled circles) and for the control group (open boxes) with the respective median levels indicated by horizontal black lines for each group and visit. (c) Relative changes of sIgE-levels to birch (left) and grass (right) are displayed for the same subjects from (a) and (b) (top-charts: apheresis group, bottom-charts: control group). Weeks of study duration are shown underneath the x-axes with birch- and grass seasons highlighted by yellow boxes and treatment weeks in purple. Dashed horizontal lines indicate baseline levels. AV – visit apheresis group; CV – visit control group. EBioMedicine 2017 17, 119-133DOI: (10.1016/j.ebiom.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Fig. 5 Changes in peak flow and symptom scores. (a) Peak flow results (y-axis: l/s), (b) overall severity of allergy-related symptoms (y-axis: VAS – visual analogue scale) and (c) severity of lung symptoms (y-axis: lung symptom score), based on daily assessment by the patients, are shown for the complete study period (x-axes: days from treatment start). Blue curves represent results from the apheresis group and red curves from the control group. Error bars show mean values, ±SD. Treatment weeks are highlighted by purple boxes, birch and grass pollen seasons by yellow boxes. EBioMedicine 2017 17, 119-133DOI: (10.1016/j.ebiom.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Fig. 6 In vitro IgE-depletion from serum samples after addition of Omalizumab. Two serum samples with total IgE-levels<300U/ml (a, low IgE) or >1400U/ml (b, high IgE), without (yellow bars) and with different IgE-to-Omalizumab ratios (x-axes: 1:1 – pink bars; 1:40 – brown bars) were applied to IgEnio adsorber material. Relative depletion rates of total-IgE are shown (y-axes). EBioMedicine 2017 17, 119-133DOI: (10.1016/j.ebiom.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

EBioMedicine 2017 17, 119-133DOI: (10.1016/j.ebiom.2017.02.007) Copyright © 2017 The Authors Terms and Conditions